Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma

BACKGROUND: Axitinib, a selective and potent tyrosine kinase inhibitor of vascular endothelial growth factor receptors, was available to patients from Canada and Australia, prior to regulatory approval of axitinib in these countries, for treatment of clear-cell metastatic renal cell carcinoma (mRCC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Karakiewicz, Pierre I, Nott, Louise, Joshi, Abhishek, Kannourakis, George, Tarazi, Jamal, Alam, Mahmood
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869634/
https://www.ncbi.nlm.nih.gov/pubmed/27274281
http://dx.doi.org/10.2147/OTT.S102578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869634/
https://www.ncbi.nlm.nih.gov/pubmed/27274281
http://dx.doi.org/10.2147/OTT.S102578

Ejemplares similares